Lifeward is a recapitalized rehab-robotics company whose second-quarter rebound proves demand for ReWalk and AlterG still exists, yet the equity remains a race between that commercial pulse and a cash clock that the Oramed partnership only reset, not removed. The investment debate is whether Medicare-cleared personal exoskeletons plus a recovered anti-gravity treadmill franchise can outrun dilution, a four percent royalty on ReWalk, and a board that just walked away from the table. The market is capitalizing the ordinary shares at roughly $21 million, a price that treats the franchise as an option on conversion rather than as a going business that already funds itself. That gap is the entire case.
The March close of the Oramed partnership is the event that reset the clock. Lifeward issued a large equity-and-warrant package and took in convertible notes so it could keep shipping hardware instead of running the coffers dry. In exchange, Oramed sits near a control stake, collects a four percent share of ReWalk net sales for as long as a decade, and parked a clinical oral-insulin program inside a company that still lives or dies on rehab hardware. The second-quarter print then showed the hardware can still grow. Revenue reached $6.6 million. That is a 16% lift from the year-ago quarter, and it is the strongest quarterly take since late 2024. AlterG recovered on domestic unit flow after the first-quarter manufacturing stall. ReWalk rose on European placements rather than on a sudden domestic Medicare flood.
The same quarter that restored the top line also advertised why the recap is not a clean rescue. Gross margin slipped to 41% from 44% as tariffs, currency, and the new Oramed royalty hit cost of sales. The GAAP net loss widened because warrant and derivative marks added a large non-cash charge. Chairman Bob Marshall and two fellow directors left in mid-August, and finance chief Almog Adar set a late-September exit. A company that just sold a large slice of itself does not usually lose its chair, two directors, and its finance chief in the same news cycle unless the partnership is already straining the boardroom. The strongest counterargument is simple: the hardware is growing again, cash is no longer measured in weeks, and Medicare plus three large Medicare Advantage plans finally give ReWalk a payer path that did not exist for most of the product's life.
The next few quarters resolve whether the Ottobock Care clinic pilot and Medicare Advantage coverage at Aetna, Humana, and UnitedHealthcare convert the ReWalk pipeline into cash faster than first-half operating burn consumes the pro forma cash pile. If placements stay lumpy and the second financing tranche stays locked behind a steep ReWalk sales jump or a high share print, the equity remains a serial-raise residual on a thin franchise. Four variables decide the argument: ReWalk placement conversion under Medicare and the Ottobock channel, quarterly cash use versus the recap cash, gross margin under the Oramed royalty, and who actually controls the company after the August exits.